Company Snapshot
- Ticker
- JNJ
- Name
- JOHNSON & JOHNSON
- Sector
- Healthcare
- Currency
- USD
- Relative Volume
- 1.71
- Market Cap
- 368943
- Volume
- 16,468,476
- Avg Volume (3M)
- 9,638,919
JNJ
JOHNSON & JOHNSON
Last update recent
206.54
+6.58
(+3.29%)
Market Cap
368943
Dividend Yield
0.00%
1Y Return
2.54%
Beta
-0.13
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 88821000000
- EPS
- 5.79
- Dividend / Share
- 4.91
- Total Dividends
- $0.00
- Dividend Yield
- 3.4%
- Net Income
- 14,066,000,000
- Net Margin
- 15.84%
- Payout Ratio
- 84.1
- Qtly Growth YoY
Valuation & Quality
- P/E
- 26.2
- Forward P/E
- P/S
- 4.2
- P/B
- 5.2
- Beta
- -0.13
- Debt / Equity
- 1.52
- Current Ratio
- 1.11
- Return on Equity
- 19.9%
- Return on Assets
- 7.9%
Technicals & Returns
- Distance vs 200 DMA
- -2.09%
- 200 DMA
- 156.51
- Distance vs 50 DMA
- -3.96%
- 50 DMA
- 159.56
- Return 1Y
- 2.54%
- Return YTD
- 6.81%
- Beta (Trailing)
- -0.13
- Relative Volume
- 1.71
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hemato Read more
- Name
- JOHNSON & JOHNSON
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Joaquin Duato
- Employees
- 131,900
- IPO Date
- 1943-01-02
- Phone
- 732 524 0400
- Address
- One Johnson & Johnson Plaza, New Brunswick, NJ
- Website
- https://www.jnj.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Last Payout
2024-08-27 • $1.24
Latest News
Curated headlines from premium sources.
Forget the 2.8% Social Security Increase. These Aristocrats Pay You 4% to 7% More Annually
The Social Security Administration announced in October that beneficiaries will receive a 2.8% cost-of-living adjustment (COLA) in 2026, following a 2.5% increase in 2025.
California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson
LOS ANGELES--(BUSINESS WIRE)--A Los Angeles Superior Court jury on Friday delivered a $40 million verdict against Johnson & Johnson. The trial involved two women who developed ovarian cancer after decades of using the company's talc-based baby powder products. The award to plaintiffs Monica Kent and Deborah Schultz, and her husband, Dr. Albert Schultz, totals $40 million in compensatory damages. The California trial is the first of 10 or more trials expected through the first half of 2026 i.
5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine
Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals.
AQR Capital Management LLC Has $728.72 Million Stock Holdings in Johnson & Johnson $JNJ
AQR Capital Management LLC trimmed its position in Johnson and Johnson (NYSE: JNJ) by 8.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,795,489 shares of the company's stock after selling 470,221 shares during the period. Johnson and Johnson makes
Ameriprise Financial Inc. Cuts Stock Holdings in Johnson & Johnson $JNJ
Ameriprise Financial Inc. cut its position in shares of Johnson and Johnson (NYSE: JNJ) by 0.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,200,118 shares of the company's stock after selling 82,472 shares during the period. Johnson and Johnson accounts for
These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same?
A notable bank and a major investment management firm bought more shares of Johnson & Johnson. The healthcare giant has performed well this year despite some significant headwinds.